Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 325Uterine Cervical Neoplasms 131Endometrial Neoplasms 109Breast Neoplasms 99Carcinoma, Non-Small-Cell Lung 85Fallopian Tube Neoplasms 77Colorectal Neoplasms 74Carcinoma, Ovarian Epithelial 71Neoplasms 63Pancreatic Neoplasms 62Stomach Neoplasms 59Melanoma 57Neoplasm Metastasis 51Triple Negative Breast Neoplasms 49Squamous Cell Carcinoma of Head and Neck 43Prostatic Neoplasms 42Lung Neoplasms 41Esophageal Neoplasms 40Head and Neck Neoplasms 39Urinary Bladder Neoplasms 32Carcinoma, Renal Cell 31Sarcoma 29Recurrence 28Small Cell Lung Carcinoma 26Colonic Neoplasms 25Carcinoma, Hepatocellular 24Carcinoma, Transitional Cell 20Uterine Neoplasms 16Peritoneal Neoplasms 15Mesothelioma 15

Interventions

ipatasertib 1Specimen Handling 1Megestrol Acetate 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma × Gynecologic × Clear all
NCT05538897 2026-05-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡